Privia Health Group (NASDAQ:PRVA) Director Matthew Shawn Morris Sells 53,722 Shares of Stock

Privia Health Group, Inc. (NASDAQ:PRVA) Director Matthew Shawn Morris sold 53,722 shares of the company’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $27.24, for a total transaction of $1,463,387.28. Following the completion of the transaction, the director owned 68,188 shares of the company’s stock, valued at $1,857,441.12. This trade represents a 44.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Matthew Shawn Morris also recently made the following trade(s):

• On Thursday, July 2nd, Matthew Shawn Morris sold 59,037 shares of Privia Health Group stock. The shares were sold at an average price of $27.33, for a total transaction of $1,613,481.21.
• On Monday, June 29th, Matthew Shawn Morris sold 63,212 shares of Privia Health Group stock. The stock was sold at an average price of $25.33, for a total transaction of $1,601,159.96.
• On Friday, June 26th, Matthew Shawn Morris sold 88,110 shares of Privia Health Group stock. The stock was sold at an average price of $25.33, for a total transaction of $2,231,826.30.
• On Friday, May 1st, Matthew Shawn Morris sold 17,096 shares of Privia Health Group stock. The stock was sold at an average price of $24.99, for a total transaction of $427,229.04.
• On Monday, May 4th, Matthew Shawn Morris sold 1,017 shares of Privia Health Group stock. The shares were sold at an average price of $24.96, for a total transaction of $25,384.32.

Privia Health Group Price Performance

Shares of Privia Health Group stock opened at $27.23 on Wednesday. The business has a 50-day moving average of $23.59 and a 200-day moving average of $23.06. The company has a market capitalization of $3.43 billion, a PE ratio of 170.20, a P/E/G ratio of 2.15 and a beta of 0.83. Privia Health Group, Inc. has a 1-year low of $18.77 and a 1-year high of $27.70.

Analysts Set New Price Targets

A number of brokerages have issued reports on PRVA. Barclays cut their target price on Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 26th. Weiss Ratings upgraded shares of Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, July 2nd. Evercore set a $26.00 price target on shares of Privia Health Group in a report on Wednesday, April 8th. Finally, Canaccord Genuity Group reduced their price objective on shares of Privia Health Group from $35.00 to $34.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Eleven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.15.

Hedge Funds Weigh In On Privia Health Group

Several large investors have recently added to or reduced their stakes in PRVA. GAMMA Investing LLC increased its stake in Privia Health Group by 14.0% during the second quarter. GAMMA Investing LLC now owns 4,819 shares of the company’s stock valued at $124,000 after purchasing an additional 592 shares during the last quarter. Harbor Investment Advisory LLC acquired a new position in shares of Privia Health Group in the 2nd quarter valued at about $69,000. Central Pacific Bank Trust Division boosted its holdings in shares of Privia Health Group by 456.5% in the 2nd quarter. Central Pacific Bank Trust Division now owns 7,001 shares of the company’s stock valued at $180,000 after buying an additional 5,743 shares during the period. Alpine Woods Capital Investors LLC bought a new stake in shares of Privia Health Group during the 1st quarter valued at about $231,000. Finally, Edgestream Partners L.P. bought a new stake in shares of Privia Health Group during the 1st quarter valued at about $2,847,000. 94.48% of the stock is currently owned by institutional investors.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.